TRA2B and neoplasm: Zhang et.al demonstrated that bone mesenchymal stem cell (BMSC)-derived EVs could be transferred into OS cells to inhibit tumor progression by targeting transformer 2β homolog (TRA2B), before subsequently proposing the potential of miR-206 and TRA2B as novel therapeutic targets [131].